Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00091416 · ClinicalTrials.gov registry record · Phase 1

Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
70
Enrollment target
8
Study locations

NCT00091416: Completed Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00091416 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 70 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (84% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00091416, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
70 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVADV014-00-VP, when given as a vaccine booster to HIV uninfected adults who participated in HVTN 052.

Conditions Studied

HIV Infections

Interventions

  • BIOLOGICAL VRC-HIVADV014-00-VP

Study Locations (8)

New York

  • HIV Prevention & Treatment CRS - New York
  • Univ. of Rochester HVTN CRS - Rochester

Maryland

  • Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore - Baltimore

Massachusetts

  • Fenway Community Health Clinical Research Site (FCHCRS) - Boston

Missouri

  • Saint Louis Univ. School of Medicine, HVTU - St Louis

Rhode Island

  • Miriam Hospital's HVTU - Providence

Tennessee

  • Vanderbilt Vaccine CRS - Nashville

Washington

  • FHCRC/UW Vaccine CRS - Seattle

Trial Details

FieldValue
Enrollment Target 70 participants
Est. Completion 2006-05
Phase Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00091416 record still lists

NCT00091416 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (84% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which VRC-HIVADV014-00-VP is the first listed.

NCT00091416 lists 8 locations in 7 states (New York, Maryland, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT00091416 about?

NCT00091416 is a clinical study titled "Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052". The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVADV014-00-VP, when given as a vaccine booster to HIV uninfected adults who participated in HVTN 052.

What is the current status of trial NCT00091416?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. Estimated completion is 2006-05.

What conditions does trial NCT00091416 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00091416?

The interventions under investigation include: VRC-HIVADV014-00-VP (BIOLOGICAL).

Who is sponsoring clinical trial NCT00091416?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00091416 being conducted?

This trial has 8 study locations across Maryland, Massachusetts, Missouri, New York, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00091416's enrollment target sits among peer trials

70 313th of 542 higher than 228 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Related registry views

Source: ClinicalTrials.gov NCT00091416, the US trial registry maintained by the National Library of Medicine. NCT00091416 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.